Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders
Minoryx Therapeutics and the Neuraxpharm Group enter into a license…
Minoryx Therapeutics and the Neuraxpharm Group enter into a license agreement for the European rights to leriglitazone, which is currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).